Global News

The hunt for an HIV vaccine

Monday, August 1, 2016

The Pulse on Global Trials by Matthew Howes

In the 1980s, HIV was a death sentence. Today, three decades later, clinical research has produced therapeutic breakthroughs that have turned HIV into a chronic yet manageable disease. Drugs that approach the disease from different angles, in combination with each other, are able to reduce viral load—the amount of virus in the body—to levels that are undetectable.

[Read More]

Astellas launches DigiTx Partners in partnership with MPM Capital

Friday, July 29, 2016

Astellas Pharma has launched DigiTx Partners, a digital health investment company, in partnership with MPM Capital. DigiTx Partners will invest in the digital health space broadly, with a special focus on companies which create solutions that improve patient outcomes and provide substantial synergy with a broader pharma business. Although the emphasis will be on earlier stage companies, investments will be made in both startups and growth stage companies.

[Read More]

INC Research launches Vaccine Catalyst Site Network

Thursday, July 28, 2016

INC Research Holdings, a global phase I to IV CRO, has launched the company’s Vaccine Catalyst Site network as part of its Catalyst program introduced earlier this year to strengthen collaborations with clinical research sites worldwide, ultimately enhancing patient focus and optimizing study delivery to drive improved predictability and increased efficiency for customers. INC selected 40 high-performing clinical research sites to participate in the initial launch of its Vaccine Catalyst Site network, which was formed to respond to the rapid growth and strong pipeline of vaccine studies.

[Read More]

LabCorp to acquire Sequenom

Thursday, July 28, 2016

Laboratory Corporation of America Holdings (LabCorp), a healthcare diagnostics company, and Sequenom, a pioneer in non-invasive prenatal testing (NIPT) for reproductive health, have entered into a definitive agreement and plan of merger under which LabCorp would acquire all of the outstanding shares of Sequenom in a cash tender offer for $2.40 per share, or an equity value of $302 million, which represents a total enterprise value of approximately $371 million, including net indebtedness.

[Read More]

pSivida plans to consolidate all R&D in current U.S. facility

Wednesday, July 27, 2016

pSivida, a leader in the development of sustained release drug delivery products primarily for eye diseases, is implementing a site consolidation plan in support of its product development program and plans to conduct all future research and product development in a single location. Subject to an employee consultation process required by local U.K. law, pSivida proposes to close its research facility in Malvern, U.K. and locate all research and product development activities in the company’s state-of-the-art, cGMP facility in Watertown, Massachusetts.

[Read More]

Wiley launches Wiley Spectra Lab

Tuesday, July 26, 2016

Wiley has launched Wiley Spectra Lab, a new and flexible expert spectral data system that uses empirical data and advanced software to help chemists, toxicologists, and life scientists confidently identify chemical substances. Wiley Spectra Lab provides access to these data in a convenient, secure cloud environment.

[Read More]